Abstract
In our previous study, we demonstrated that the use of the autoluminescent Mycobacterium tuberculosis as a reporter strain had the potential to drastically reduce the time, effort, animals and costs consumed in evaluation of the activities of drugs and vaccines in live mice. However, the strains were relatively unstable and lost reporter with time without selection. The kanamycin selection marker used wasn't the best choice as it provides resistance to amino glycosides which are an important class of second line drugs used in tuberculosis treatment. In addition, the marker could limit utility of the strains for screening of new potential drugs or evaluating drug combinations for tuberculosis treatment. Limited selection marker genes for mycobacterial genetic manipulation is a major drawback for such a marker-containing strain in many research fields. Therefore, selectable marker-free, more stable autoluminescent mycobacteria are highly needed. After trying several strategies, we created such mycobacterial strains successfully by using an integrative vector and removing both the resistance maker and integrase genes by Xer site-specific recombination in one step. The corresponding plasmid vectors developed in this study could be ...Continue Reading
References
Jun 6, 1991·Nature·C K StoverG F Hatfull
Nov 1, 1990·Molecular Microbiology·S B SnapperW R Jacobs
Nov 15, 1996·FEMS Microbiology Letters·B J Wards, D M Collins
Jul 22, 1998·FEMS Microbiology Letters·M K WinsonG S Stewart
Feb 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·E J RubinJ J Mekalanos
Feb 7, 2001·Journal of Clinical Microbiology·A Van RieT C Victor
Apr 20, 2001·International Journal of Medical Microbiology : IJMM·B SpringerE C Böttger
Jul 18, 2002·IUBMB Life·Thomas C VictorRobin Warren
Mar 7, 2003·FEMS Microbiology Letters·Wladimir MalagaChristophe Guilhot
Mar 26, 2003·Infection and Immunity·Marcus A Horwitz, Günter Harth
Jan 14, 2004·Nucleic Acids Research·Beatrice Saviola, William R Bishai
Dec 21, 2006·Nature Methods·Julia C van Kessel, Graham F Hatfull
Jun 28, 2008·PloS One·Huajun ZhengYing Zhang
Sep 5, 2009·American Journal of Respiratory and Critical Care Medicine·Tianyu ZhangEric L Nuermberger
Apr 28, 2010·Antimicrobial Agents and Chemotherapy·Tianyu ZhangEric L Nuermberger
Jun 15, 2010·Applied and Environmental Microbiology·Alessandro CascioferroRiccardo Manganelli
Aug 10, 2010·Gene·Jason HuffMichael Niederweis
Jan 19, 2012·PloS One·Tianyu ZhangEric L Nuermberger
Jan 25, 2012·Lancet·Samuel Loewenberg
Sep 4, 2012·Lancet·Sven Hoffner
May 2, 2013·The Journal of Antimicrobial Chemotherapy·Nuria AndreuBrian D Robertson
Oct 18, 2013·Journal of Clinical Microbiology·Yaoju TanYanlin Zhao
Dec 25, 2013·PLoS Neglected Tropical Diseases·Tianyu ZhangEric L Nuermberger
May 31, 2014·Journal of Microbiological Methods·Feng YangTianyu Zhang
Jun 5, 2014·MBio·Paras JainWilliam R Jacobs
Citations
Jul 21, 2015·ACS Medicinal Chemistry Letters·Jian TangKe Ding
Mar 10, 2016·Antimicrobial Agents and Chemotherapy·Gaëlle Guiewi MakafeTianyu Zhang
Jan 31, 2019·Archiv der Pharmazie·Niu-Niu ZhangMing Yan
Dec 18, 2019·Antimicrobial Agents and Chemotherapy·Yang LiuTianyu Zhang
Apr 11, 2017·Frontiers in Microbiology·Julius MugweruTianyu Zhang
Jan 29, 2019·Chemical & Pharmaceutical Bulletin·Jie LiangMing Yan
Feb 19, 2019·MedChemComm·Goverdhan SurineniTianyu Zhang
Aug 29, 2018·MedChemComm·Niu-Niu ZhangMing Yan
Dec 10, 2019·MedChemComm·Chungen LiYoufu Luo
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Anthi PetrouAthina Geronikaki
Apr 28, 2020·Journal of Natural Products·Zhijie YangJunying Ma
Jun 22, 2021·Antimicrobial Agents and Chemotherapy·Sheng ZengTianyu Zhang